Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum

Planta Medica

Volumn 72, Issue 6, 2006, Pages 527-532

  Subehan, ^a   Usia, Tepy ^a   Kadota, Shigetoshi ^a   Tezuka, Yasuhiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Alkamides; CYP2D6; Cytochrome P450 2D6; Drug herb interaction; Mechanism based inhibition; Piper nigrum

Indexed keywords

ALKAMIDE; CYTOCHROME P450 2D6; PLANT EXTRACT; UNCLASSIFIED DRUG;

ARTICLE; BLACK PEPPER; DRUG INHIBITION; DRUG STRUCTURE; KINETICS; LIVER MICROSOME; NONHUMAN;

AMIDES; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; HERB-DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; PHYTOTHERAPY; PIPER NIGRUM; PLANT EXTRACTS;

PIPER NIGRUM;

EID: 33744913556     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-931558     Document Type: Article

References (27)

1. Thayer WS. Biotransformation. In: DiPalma JR, DiGregorio GJ, editors. Basic pharmacology in medicine; 3rd Edition New York: McGraw-Hill Publishing Company, 1989: p 52-62
2. Guengerich FP. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1996; 24: 521-33
3. Clarke SE, Jones BC. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In: Rodrigues AD, editor. Drug-drug interactions New York: Marcel Dekker, 2002: p 55-8
4. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-90
5. Silverman RB. Mechanism-based enzyme inactivation: chemistry and enzymology I. Florida: CRC Press, 1988: p 1-30
6. Chun YJ, Ryu SY, Jeong TC, Kim MY. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab Dispos 2001; 29: 389-93
7. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochrome P450 3A4. Arch Biochem Biophys 2000; 376: 356-63
8. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67: 3102-12
9. Chan TKH, Chen J, Lee WBK. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001; 299: 874-82
10. Usia T, Watabe T, Kadota S, Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci 2005; 76: 2381-91
11. Usia T, Watabe T, Kadota S, Tezuka Y. Mechanism-based inhibition of CYP3A4 by constituents of Zingiber aromaticum. Biol Pharm Bull 2005; 28: 495-9
12. Usia T, Watabe T, Kadota S, Tezuka Y. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. Biol Pharm Bull 2005; 28: 1021-4
13. Jo B. Medicinal herb index in Indonesia. Jakarta: PT Eisai Indonesia, 1995: p 275
14. Tsukamoto S, Cha BC, Ohta T. Dipiperamides A, B, and C: bisalkaloids from the white pepper Piper nigrum inhibiting CYP3A4 activity. Tetrahedron 2002; 58: 1667-71
15. Tsukamoto S, Tomise K, Miyakawa K, Cha BC, Abe T, Hamada T et al. CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepper. Bioorg Med Chem 2002; 10: 2981-5
16. Koul S, Koul JL, Taneja SC, Dhar KL, Jamwal DS, Singh K et al. Structure-activity relationship of piperine and its synthetic analogues for their inhibitory potentials of rat hepatic microsomal constitutive and inducible cytochrome P450 activities. Bioorg Med Chem 2000; 8: 251-68
17. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Metabolism-dependent inhibition of CYP3A4 and CYP2D6 by extracts from 26 herbal medicines. J Tradit Med 2004; 21: 281-6
18. Rodrigues AD. Measurement of human liver microsomal cytochrome P450 2D6 activity using [O-methyl-14C]dextromethorphan as substrate. In: Johnson EF, Waterman MR, editors. Cytochrome P450 New York: Academic Press, 1996: p 86-195
19. Deans SG. Book reviews: black pepper, Piper nigrum. Medicinal and aromatic plants-industrial profiles. Phytochemistry 2001; 58: 827-9
20. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fomm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302: 645-50
21. Yuan R, Madani S, Wei X, Reynolds K, Huang S. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002; 30: 1311-9
22. Bertelsen KM, Venkatakrishnan K, Moltke LLV, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 289-93
23. Guengerich FP, Muller ED, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986; 30: 287-95
24. Nelson SD. Metabolic activation and drug toxicity. J Med Chem 1982; 25: 753-65
25. Moruno-Davila MA, Garrido-deSolo C, Garcia-Moreno M, Havsteen BH, Garcia-Sevilla F, Garcia-Canovas F et al. Kinetic analysis of enzyme systems with suicides substrate in the presence of a reversible competitive inhibitor, tested by simulated progress curves. Int J Biochem Cell Biol 2001; 33: 181-91
26. Walsh C. Suicide substrates: mechanism-based enzyme inactivators. Tetrahedron 1982; 38: 871-909
27. Murray M. Mechanism of inhibitory and regulatory effects of methyl-enedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 2000; 1: 67-84